Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals

Western biopharma companies are seeking partnerships with Chinese firms to bolster their pipelines as major patents expire, threatening revenue. The "patent cliff" refers to the looming loss of exclusivity on top-selling drugs, which could lead to significant revenue declines for these companies. In response, they're turning to China, where a growing number of innovative biotech firms are developing promising new treatments.

This trend is driving multibillion-dollar deals between Western and Chinese biopharma companies. For Chinese firms, these partnerships offer access to global markets, expertise, and resources. For Western companies, they provide a way to tap into China's innovative biotech sector and replenish their pipelines with new drugs. The deals also reflect a shift in the global biopharma landscape, where emerging markets like China are increasingly playing a key role in driving innovation.

As the patent cliff draws closer, we can expect to see more deals between Western and Chinese biopharma companies. Trade-watchers should keep an eye on how these partnerships play out, particularly in terms of regulatory approvals, market access, and intellectual property protection. Additionally, the success of these collaborations will depend on the ability of Western and Chinese firms to navigate cultural and operational differences, making effective partnerships a crucial factor in their success.

Originally reported by cnbc.com. Trade-News adds analysis for finance & markets readers.